| 治疗成人失眠新药Dayvigo的研究现状 |
| |
| 引用本文： | 曹凯风,赵志刚,李新辰.治疗成人失眠新药Dayvigo的研究现状[J].中国临床药理学杂志,2021(6):768-771. |
| |
| 作者姓名： | 曹凯风 赵志刚 李新辰 |
| |
| 作者单位： | 首都医科大学附属北京天坛医院药学部 |
| |
| 基金项目： | 中国毒理学会临床毒理专项基金资助项目(CST2019CT302)。 |
| |
| 摘 要： | Dayvigo是美国食品药品监督管理局于2019年12批准的一种用于治疗成人失眠的新型双食欲素受体拮抗药,化学成分为lemborexant。临床研究结果显示Davigo能够显著改善失眠患者的入睡速度与睡眠维持时间。现对其作用机制、药理毒理研究、临床研究结果、安全性、有效性、注意事项等作一综述。
|
| 关 键 词： | Dayvigo 失眠 双食欲素受体拮抗剂 |
Research status on Dayvigo—A new approved drug for treatment of adult patients with insomnia |
| |
| CAO Kai-feng,ZHAO Zhi-gang,LI Xin-chen.Research status on Dayvigo—A new approved drug for treatment of adult patients with insomnia[J].The Chinese Journal of Clinical Pharmacology,2021(6):768-771. |
| |
| Authors: | CAO Kai-feng ZHAO Zhi-gang LI Xin-chen |
| |
| Affiliation: | (Deparment of Pharmacy,Beijing Tiantan Hospital,Capital Medical University^Beijing 100070,China) |
| |
| Abstract: | Dayvigo is an orexin receptor antagonist indicated for the treatment of adult patients with insomnia, approved by the US Food and Drug Administration, in Dec, 2019, its composition is lemborexant. Clinical research results show that Davigo can significantly improve the speed of falling asleep and the duration of sleep in patients with insomnia. Now, we reviewed the mechanism of action, pharmacology and toxicology research, clinical research, safety and precautions about Dayvigo. |
| |
| Keywords: | Dayvigo insomnia orexin receptor antagonist |
| 本文献已被 维普 等数据库收录！ |
